We all want to live long healthy lives – as evidenced by the multi-trillion dollar wellness industry.
In our pursuit for healthy living, there are an overwhelming number of diets, fitness apps and exercise programs to choose from. The problem is that finding what works for you can be hit and miss. This is because we are all genetically different.
Fitgenes helps to take the guesswork out of wellness planning. Take weight loss as an example. CarbChoice by Fitgenes is a simple home DNA test. For $149 it identifies an individual’s response to a key dietary issue with a genetic trigger and gives a plan for success. There is much more. FoodChoice by Fitgenes reports on the genetic risk of food intolerances and sensitivities and the risk of food allergies, while the company’s flagship Health and Wellbeing Report is supplied exclusively to practitioners to assist in the assessment and management of chronic diseases, immunity issues and weight management. With the support of the Fitgenes Accredited Health Practitioners network, this knowledge becomes applied precision wellness – a roadmap to live a long and healthy life.
FITGENES - Personalised DNA-based, wellness plans - tailored, reliable, affordable, and accessible
The global wellness genomics market is high-growth with 13.2% CAGR; and predicted to hit US$9 billion by 2026. Nutrigenomics, a subset of that market, is set to double in the next few years to approximately $1 billion.
Fitgenes business model not only delivers tailored, reliable, affordable and accessible wellness plans, its plans are integrated with a growing allied health network of practitioners – in other words, has a unique distribution channel that makes its test results even more meaningful.
With increased adoption of DNA-based testing by health professionals, Fitgenes is building its pipeline amongst the 830,000+ medical doctors in the USA, and over 43,000 GPs in Australia, as well as the additional millions of allied health professionals globally.
This pipeline is being developed to increase Fitgenes’ already healthy 11% year on year growth in business income.
As a pioneer of genetics-based health management, Fitgenes has used technology advances to significantly improve report quality, take advantage of decrease testing costs and improve scalability. Here are some recent progress highlights:
Fitgenes achieved 11% income growth in 2020 over 2019, during COVID and prior to adding new distribution partners.
While the connection between genetics and nutrition is well known, until recently, the ability to commercialise DNA-based health solutions has been limited due to high cost of testing and regulatory restrictions. As a result, the market to date has been dominated by commoditised direct-to-consumer reports that can lack scientific rigour and often void of essential context, such as a person’s goals, stage of life or existing health status.
However, this ‘isolated’ testing model is under threat, with medical research consensus and regulatory requirements strengthening in favour of practitioner delivery of DNA-based health and wellness reports.
Fitgenes’ business model has a primary focus that practitioner channel, with a network of accredited health practitioners using and trained in our methodology.
People are living longer but are not living better – the last 20 years of a modern lifespan are very often marred by debilitating chronic disease. Implementing nutrition, dietary, lifestyle and even exercise advice based on your unique DNA has been demonstrated to assist in the prevention and management of long-term health, of many acute diseases and to assist weight management and has increasing mainstream acceptance (AMA Australia, 2020).
Fitgenes is an innovative DNA-based healthcare business focused on long-term wellness, obesity and cardiometabolic health. We are an early mover in the growing global nutrigenomics (DNA testing for dietary health) industry and the increasing shift to the biomedical-driven prevention of chronic disease, including but not limited to, obesity, diabetes, cardiovascular disease, poor immune function, and to improve sports performance, injury prevention and recovery.
An investment in Fitgenes provides an opportunity to participate in the most-established DNA wellness provider in the practitioner channel, as that sector expands while the direct to consumer market is threatened by greater regulatory controls, commoditisation, and lack of medical industry acceptance.
1Question Fireside Chat available here
Want to learn a TikTok move? ….sure, but first ...what’s 7 x 8? Want to post to Instagram? Go for it .. but first ….. What’s the square root of 6,384 (just kidding but you get the idea).
1Question is an app that leverages existing screen habits to create micro learning moments. Lots of them. Every. Single. Day. Advanced AI understands the student’s strengths and weaknesses and customizes questions to accelerate learning.
1Question is backed by the Google accelerator program for User Acquisition. They are a company that is born global with a first mover advantage and a gigantic total addressable market.
ATO approved ESIC status delivering substantial investor tax benefits.
Before investing please consider the offer document and the general risk warning.
SPP = Share Purchase Plan
The top 300 companies average 27 SPPs p.a.
SPPs priced @ avg discount of 10% to trading price
SPPs usually accompany an institutional placement
Existing shareholders can apply for $30,000/SPP
Buys you 1-share in 300 companies
Only applies for SPPs that are in-the-money
Automatically applies + sells shares @market price
Harvests the SPP discount to reinvest in next SPP
Since inception, SPP Harvester clients have earnt an average 13.1% on the capital invested in SPPs, over an average holding period per SPP of 22 days.
Acquire a holding in 300 companies brokerage-free - saving $3300 - until 30 June
IPO underwritten up to approx $48.6 million. OnMarket has a limited allocation.
Tamboran Resources Ltd (ASX: TBN) is a public company that intends to play a constructive role in the global energy transition towards a lower carbon future by developing low CO2 unconventional natural gas resources in the Beetaloo Sub-basin in the Northern Territory of Australia.
With interests in three exploration permits, including a JV with Santos at EP161, Tamboran has estimated net prospective resources of 31 Tcf. Their aim is to provide affordable gas to local Northern Territory markets and supply gas to the east coast of Australia to meet forecast domestic gas shortfalls.
R3D Resources Limited (ASX: R3D) through the acquisition of Tartana Resources Limited aims to become a significant copper-gold explorer, developer and producer in the Chillagoe Region in North Queensland. These projects vary in maturity from granted mining leases, mining lease applications and exploration permits. The Tartana mining leases contain an existing heap leach – solvent extraction – crystallisation plant which has been held in care and maintenance since 2014. Work has begun to restart this plant to provide future cash flow through the sale of copper sulphate.
In Tasmania, Tartana has secured permits to excavate and screen to export a further 335,000 tonnes of low-grade zinc furnace slag/matte from its Zeehan stockpiles in Western Tasmania, and recently commenced its 5th 22,000 tonne shipment of zinc slag to South Korea.
goPassport is a unique and highly relevant travel risk SaaS platform in the new Travel/Health Tech space. The business started at the outset of Covid in March 2020 and has since built out a powerful, complex but user friendly & scalable software following the successful crowd sourced equity raise of $0.8m.
Having engaged deeply with key levels of state & federal government, travel industry, health authorities and border protection agencies, goPassport is now well placed to play a vital role in the reopening of borders and the recommencement of the international travel industry.
This offer is restricted to professional, sophisticated, and experienced investors. More info here.
People spend big on wellness (it accounts for 5.3% of global economic output). But, 80% of consumers find the market is full of conflicting data, making this spend haphazard. Solving this problem is the emerging wellness genomics sector - a high-growth market (13.2% CAGR), predicted to hit US$9 billion by 2026.
Meet Fitgenes. With a range of wellness focus areas, Fitgenes’ genomic products cut through the clutter - delivering wellness plans tailored to the specific requirements of an individual. But it is the distribution network and strategy that sets this growing heath-tech business apart.
Before investing please consider the offer document and the general risk warning.